MA46660A - Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide - Google Patents

Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide

Info

Publication number
MA46660A
MA46660A MA046660A MA46660A MA46660A MA 46660 A MA46660 A MA 46660A MA 046660 A MA046660 A MA 046660A MA 46660 A MA46660 A MA 46660A MA 46660 A MA46660 A MA 46660A
Authority
MA
Morocco
Prior art keywords
adenine dinucleotide
nicotinamide adenine
recovery route
targeted administration
inhibitors
Prior art date
Application number
MA046660A
Other languages
English (en)
Inventor
Christopher Scott Neumann
Kathleen Olivas
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MA46660A publication Critical patent/MA46660A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046660A 2016-10-18 2017-10-18 Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide MA46660A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662409765P 2016-10-18 2016-10-18

Publications (1)

Publication Number Publication Date
MA46660A true MA46660A (fr) 2019-08-28

Family

ID=62019577

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046660A MA46660A (fr) 2016-10-18 2017-10-18 Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide

Country Status (14)

Country Link
US (2) US11638762B2 (fr)
EP (1) EP3528850A4 (fr)
JP (2) JP2019530697A (fr)
KR (2) KR20230144096A (fr)
CN (1) CN109843334A (fr)
AU (1) AU2017345262A1 (fr)
BR (1) BR112019006778A2 (fr)
CA (1) CA3039589A1 (fr)
EA (1) EA201990890A1 (fr)
IL (2) IL291810A (fr)
MA (1) MA46660A (fr)
MX (2) MX2019004046A (fr)
SG (1) SG11201903013SA (fr)
WO (1) WO2018075600A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
BR112019022445A2 (pt) * 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
CA3089754A1 (fr) * 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Conjugues anticorps-medicament (adc) avec des inhibiteurs de nampt
CN109776494B (zh) * 2018-12-25 2021-06-18 中国人民解放军第二军医大学 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用
CN110974975B (zh) * 2019-12-12 2023-10-20 成都百利多特生物药业有限责任公司 一种快速释放的抗体药物偶联物
CN111454327A (zh) * 2020-04-02 2020-07-28 中国人民解放军第二军医大学 一种nampt蛋白降解靶向嵌合体及其制备方法和应用
WO2023030170A1 (fr) * 2021-09-02 2023-03-09 标新生物医药科技(上海)有限公司 Composé de dégradation protéique à base de protéine cible nampt et son utilisation
WO2024052684A1 (fr) 2022-09-09 2024-03-14 MyricX Pharma Limited Conjugué anticorps-médicament comprenant un inhibiteur de nmt et son utilisation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061559A1 (fr) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Composes de cyanoguanidine n-substitues
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
RU2004136989A (ru) 2002-05-17 2005-06-27 Лео Фарма А/С (Dk) Цианогуанидиновые пролекарства
EP2357006B1 (fr) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3120861B1 (fr) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Composés intermédiaires pour la préparation de conjugués d'auristatin avec des éléments de liaison
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
WO2007008603A1 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CA2702555A1 (fr) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Agents de liaison au cd19 et utilisations de ceux-ci
WO2009086835A1 (fr) 2008-01-11 2009-07-16 Topotarget A/S Nouvelles cyanoguanidines
US8742076B2 (en) 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
MX2010011807A (es) 2008-04-30 2011-03-04 Immunogen Inc Entrelazadores y sus usos.
WO2009140418A2 (fr) * 2008-05-14 2009-11-19 Five Prime Therapeutics, Inc. Compositions et procédés pour le traitement de l’arthrite et/ou de maladies impliquant une dégénérescence du cartilage
WO2009156421A1 (fr) 2008-06-24 2009-12-30 Topotarget A/S Dérivés de l’acide squarique utilisés comme inhibiteurs du nicotinamide
RU2011111728A (ru) * 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
WO2010142735A1 (fr) 2009-06-09 2010-12-16 Topotarget A/S Dérivés de pyridinyle utilisés en tant qu'inhibiteurs de l'enzyme nicotinamide phosphoribosyltransférase
US20120270900A1 (en) * 2009-07-17 2012-10-25 Topo Target A/S Novel method of treatment
US20140294805A1 (en) 2010-09-03 2014-10-02 Kenneth W. Bair Novel compounds and compositions for the inhibition of nampt
CA2809391A1 (fr) 2010-09-03 2012-03-08 Genentech, Inc. Derives de 4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone en tant qu'inhibiteurs de nampt utilises dans le traitement de maladies telles que le cancer
MX2013005454A (es) 2010-11-15 2013-06-24 Abbvie Inc Inhibidores de nampt y rock.
EP2640704A1 (fr) 2010-11-15 2013-09-25 Abbvie Inc. Inhibiteurs de nampt
SI3156420T1 (sl) 2010-12-06 2019-05-31 Seattle Genetics, Inc. Humanizirana protitelesa za LIV-1 in njihova uporaba pri zdravljenju raka
CN103717574B (zh) 2011-05-04 2017-02-22 福马Tm有限责任公司 用于抑制nampt的新化合物和组合物
AR082889A1 (es) 2011-05-09 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones para la inhibicion de nampt
JP2014518223A (ja) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
EP2776393B1 (fr) 2011-11-11 2017-12-20 Abbvie Inc. Inhibiteurs de la nampt
WO2013082150A1 (fr) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Inhibiteurs à petite molécule de nicotinamide phosphoribosyltransférase (nampt)
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
WO2013130943A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Dérivés sulfonamides amido-benzyliques substitués par un groupe alkyle et disubstitués
WO2013127268A1 (fr) 2012-03-02 2013-09-06 Genentech,Inc. Dérivés sulfonamides et sulfones amido-benzyliques
WO2013130935A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Dérivés sulfoxydes amido-benzyliques
US9187472B2 (en) 2012-05-11 2015-11-17 Abbvie Inc. NAMPT inhibitors
EP2850081A1 (fr) 2012-05-11 2015-03-25 AbbVie Inc. Dérivés de thiazolecarboxamide utiles en tant qu'inhibiteurs de la nampt
TW201350478A (zh) 2012-05-11 2013-12-16 Abbvie Inc Ｎａｍｐｔ抑制劑
EP2852585A1 (fr) 2012-05-11 2015-04-01 AbbVie Inc. Inhibiteurs de nampt
WO2013170191A1 (fr) 2012-05-11 2013-11-14 Genentech, Inc. Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
KR101762047B1 (ko) 2012-11-05 2017-07-27 화이자 인코포레이티드 스플라이세오스타틴 유사체
WO2014074715A1 (fr) 2012-11-07 2014-05-15 Genentech, Inc. Dérivés d'amide cyclopropyle
WO2014111871A1 (fr) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited Dérivés de 4,5-dihydroisoxazole utilisés comme inhibiteurs de nampt
ITTO20130356A1 (it) 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
EP3055304A1 (fr) 2013-10-09 2016-08-17 Eli Lilly and Company Nouveaux composés de pyridyloxyacétyl tétrahydroisoquinoline utiles en tant qu'inhibiteurs de nampt
JP6701077B2 (ja) 2013-12-19 2020-05-27 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EA201692091A1 (ru) 2014-04-18 2017-04-28 Милленниум Фармасьютикалз, Инк. Хиноксалиновые соединения и их применение
TW201625641A (zh) 2014-05-22 2016-07-16 健臻公司 Ｎａｍｐｔ抑制劑及方法
US20170204092A1 (en) 2014-07-23 2017-07-20 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
SG11201701311YA (en) * 2014-09-11 2017-03-30 Seattle Genetics Inc Targeted delivery of tertiary amine-containing drug substances
CN104557863B (zh) 2014-12-18 2017-03-15 中国科学院广州生物医药与健康研究院 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用
EP3247705B1 (fr) 2015-01-20 2019-11-20 Millennium Pharmaceuticals, Inc. Composés quinazoline et quinoléine, et utilisations de ceux-ci en tant qu'inhibiteurs nampt
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
BR112019022445A2 (pt) 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco

Also Published As

Publication number Publication date
US20240016953A1 (en) 2024-01-18
CN109843334A (zh) 2019-06-04
SG11201903013SA (en) 2019-05-30
IL291810A (en) 2022-06-01
MX2023010327A (es) 2023-09-14
BR112019006778A2 (pt) 2019-10-15
IL265837B (en) 2022-05-01
US20190314519A1 (en) 2019-10-17
AU2017345262A1 (en) 2019-06-06
JP2023038355A (ja) 2023-03-16
EA201990890A1 (ru) 2019-10-31
WO2018075600A1 (fr) 2018-04-26
KR20230144096A (ko) 2023-10-13
TW201818970A (zh) 2018-06-01
CA3039589A1 (fr) 2018-04-26
KR20190074292A (ko) 2019-06-27
IL265837A (en) 2019-06-30
EP3528850A4 (fr) 2020-06-24
MX2019004046A (es) 2019-08-21
US11638762B2 (en) 2023-05-02
JP2019530697A (ja) 2019-10-24
EP3528850A1 (fr) 2019-08-28

Similar Documents

Publication Publication Date Title
MA46660A (fr) Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
MA51189A (fr) Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
SI3429591T1 (sl) Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
CY1122920T1 (el) ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ
DK3122752T3 (da) 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
IL246929B (en) 4'-difluoromethyl-substituted nucleoside compounds as inhibitors of influenza RNA replication
EA201791684A1 (ru) Селективные ингибиторы bace1
DK3359241T3 (da) Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf
DK3160958T3 (da) Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
DK2861608T3 (da) Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
MA43298A (fr) Derives heterocycliques d'indole pour des infections par le virus de la influenza
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида
DK3390412T3 (da) Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser
MA51285A (fr) Dérivés d'azaindole comme inhibiteurs de rho-kinase
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
ZA201702858B (en) 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
DK3416654T3 (da) Medicinsk anvendelse af 5'-adenosindiphosphatribose (adpr)
IT201600095893A1 (it) Metodo per implementare realta' aumentata
DK3253868T3 (da) Sammensætninger og fremgangsmåder, der omfatter anvendelsen af en bacillus agaradhaerens inulosucrase (inou)
FR3044021B1 (fr) Procede d'ionisation d'argon